Tesamorelin is documented in its prescribing information as a fixed once-daily subcutaneous injection that is not titrated to body weight or escalated over time, which sets it apart from peptides that ramp toward a target. The daily-reconstitution product ships as a lyophilized powder that the label directs be mixed with sterile water immediately before each dose, because the reconstituted solution carries no preservative and is not stable for storage. The regulatory frame matters for anyone reading past the mechanics: this is an FDA-approved drug for a specific indication, and its documented handling reflects a prescription product, not a research compound.
Tesamorelin's daily-reconstitution formulation is documented as a fixed 1.4 mg subcutaneous dose reconstituted from a 2 mg vial and injected once daily, given as a freeze-dried powder mixed with sterile water immediately before each dose.
The approved regimen documented in the prescribing information is a single fixed dose given subcutaneously once daily, seven days a week, with no drug-free days written into the schedule. What surprises many readers is that the dose does not scale to the person: the literature describes a fixed amount rather than a weight-based or titrated one, so a larger and a smaller patient receive the same delivered dose, and there is no escalation phase toward a target.
The approved regimen is documented as a fixed once-daily 1.4 mg subcutaneous dose that is neither weight-based nor titrated, serving as both the starting and the ongoing amount.
Reconstitution is documented as a sequence in which the fragile peptide is protected at every step, and the order is what separates a full-potency dose from a degraded one. The published procedure begins with sterile water for injection added to the powder vial rather than the reverse, and the handling from that point forward is deliberately gentle because agitation and foaming are reported to denature the molecule.
Published reconstitution procedures describe adding sterile water down the vial wall and dissolving the powder by gentle rolling rather than shaking, because agitation and foaming are reported to denature the peptide and reduce delivered potency.
The injection is documented as subcutaneous into the abdominal fat, the layer just beneath the skin rather than into muscle, which is why the record describes a short fine needle and a pinched skin fold. Because the drug is given every single day, the literature emphasizes site rotation as a core part of the routine: without it, the same small patch of tissue would be punctured repeatedly, and the documented consequences are lipohypertrophy and cumulative local injury.
Published administration guidance documents subcutaneous injection into abdominal fat with daily site rotation of at least one to two inches, a pattern reported to keep absorption consistent and to prevent lipohypertrophy from repeated trauma to one area.
Evening or bedtime dosing is the pattern the literature most commonly reports, and the documented reasoning ties to the body's own rhythm rather than to convenience alone. Natural growth hormone releases its largest pulse during early sleep, and because tesamorelin is documented to prompt the pituitary to release growth hormone rather than supplying it directly, timing the dose to that overnight surge lets the drug amplify a peak the body is already building.
Evening or bedtime administration is the documented convention because tesamorelin stimulates the pituitary to amplify the natural overnight growth-hormone pulse, though the literature reports that consistent 24-hour spacing matters more than the precise clock time.
The sealed lyophilized powder and its diluent are documented as stored at controlled room temperature, generally the 20 to 25 degrees Celsius range, with freezing avoided because it is reported to damage the peptide. The picture changes once the diluent is added: in the daily-reconstitution formulation the mixed solution has a very short usable window and no preservative, which is why the accepted documented practice is a fresh dose mixed immediately before each injection.
| Storage question | Sealed powder and diluent | Reconstituted solution |
|---|---|---|
| Temperature | Controlled room temperature, ~20-25°C | Prepared and used immediately |
| Freezing | Documented as avoided (damages peptide) | Not applicable |
| Preservative | Not applicable | None present |
| Usable window | Reasonably stable sealed | Very short; requires fresh mixing each dose |
The sealed powder and diluent are documented as stored at controlled room temperature near 20 to 25 degrees Celsius and protected from freezing, while the reconstituted preservative-free solution is reported to have a very short usable window that calls for fresh preparation before each dose.
The most common potency-killing error documented in the handling literature is rough treatment during mixing, since shaking hard or creating foam is reported to shear and denature the peptide so the labeled dose no longer delivers its full active amount. The cautionary picture extends past mixing: temperature abuse, measuring errors, and contamination of a preservative-free solution each carry documented consequences that can leave the tissue receiving less drug, or a compromised dose, than intended.
The handling literature documents rough mixing, temperature abuse, inaccurate diluent volume, and contamination of the preservative-free solution as the leading causes of lost potency and dosing error, several of which degrade the dose with no visible change.
Continuous daily dosing is documented as necessary because tesamorelin does not replace a hormone or make a permanent change; the record describes it as repeatedly prompting the pituitary to release the body's own growth hormone, a nudge that has to be renewed each day to keep the downstream effect alive. This is the distinction that separates it from a short curative course: the literature reports that the pituitary reverts to baseline once stimulation stops, and the treated visceral fat tends to return.
Because tesamorelin stimulates the pituitary rather than replacing a hormone, the literature documents that its visceral-fat reduction builds over months of continuous daily dosing and reverses toward baseline when treatment stops, making indefinite adherence central to holding the effect.
Self-administration is documented as depending on a small standing kit and a repeatable sequence rather than on any single step, and the honest read is that the routine's safety rests on both being kept intact day after day. The record describes the injection as subcutaneous, which is why a short fine needle of a small gauge is documented as appropriate for reaching the fatty layer just under the skin rather than muscle.
Self-administration is documented as requiring a standing kit of powder vial, sterile water, syringe, needle, alcohol swabs, and a sharps container, paired with a fixed subcutaneous sequence of swabbing, reconstituting, clearing air, injecting into a pinched abdominal fold, and disposing of sharps rigidly.
Educational use only. This article describes what the published scientific and clinical literature reports about Tesamorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
